Module 3: Nonclinical Development of Antisense Oligonucleotide for Spinal Muscular Atrophy
Recorded On: 04/25/2024
Nusinersen has been evaluated in a nonclinical program to support treatment of spinal muscular atrophy (SMA) using lumbar intrathecal (IT) administration. SMA is an autosomal recessive neuromuscular disease that primarily affects infants and children and is characterized by degeneration of the motor neurons in the spinal cord. Deletions in the survival motor neuron gene (SMN1) result in loss of SMN protein and eventual death of motor neurons. A duplicate gene, SMN2, is not functional due to a splicing defect that skips exon 7 and results in truncated SMN protein. Nusinersen is a fully 2'-O-methoxyethyl modified phosphorothioate antisense oligonucleotide designed to bind to SMN2 pre-mRNA and facilitate inclusion of exon 7, resulting in full-length SMN protein.
PK studies established the minimum tissue concentration that increased exon 7 in mRNA in transgenic mice (2 to 10 µg/g), and the half-life in monkey CNS tissue (~150 days). Toxicology studies included a single-dose IT study in cynomolgus monkeys, 14-week and 53-week repeat-dose IT toxicity studies in juvenile monkeys, 13-week SC study in juvenile CD-1 mice, and SC reproductive toxicity studies in CD-1 mice and NZW rabbits. Genetic toxicology studies (Ames test, chromosomal aberration, mouse micronucleus) were negative. The monkey was chosen for repeat-dose IT toxicology studies and a 53-week study in monkeys established loading and maintenance dose regimen, used to maximize CSF and CNS tissue exposure. Animals received 5 weekly IT doses at 0.3, 1, and 4 mg/dose followed by dosing every 6 weeks (total of 13 IT doses), with a NOAEL at the high dose (4 mg/dose). In clinical studies, infants received 4 loading doses followed by maintenance doses once every 4 months. Safety margins were based on the approximate 10-fold difference in CSF volume between monkeys and humans and the total cumulative yearly dose. The NOAEL of 4 mg/dose (administered 13 times/year) converts to a total human equivalent dose of 520 mg/year, and provides a safety margin of 14-fold compared to the chronic yearly maintenance dose of 36 mg/year in patients.
Scott Henry, PhD
Vice President of Nonclinical Development
Ionis Pharmaceuticals, Inc.
Dr. Scott Henry received a PhD in Biochemistry from North Dakota State University in 1991, studying the phosphorylation and regulation of the glycogen synthesis pathway in the heart. Following his PhD, he was a postdoctoral fellow at Parke Davis in Ann Arbor, Michigan, in the Department of Toxicology until 1993. He then joined Ionis Pharmaceuticals, Inc. as a Senior Scientist in the department of toxicology. Along with a team of dedicated colleagues, he has characterized and studied the mechanisms of various toxicities that include the effects of oligonucleotide treatment on clotting time prolongation, alternative complement pathway activation, proinflammatory effects in rodents, platelet alterations and the effects related to the accumulation of oligonucleotide in kidney. Now as Vice President of Nonclinical Development at Ionis Pharmaceuticals, Inc. he has participated in the development of approximately 8 different phosphorothioate oligodeoxynucleotides and over 30 different 2’-MOE modified phosphorothioate oligonucleotides.